Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Sterol analysis identified four Candida albicans erg3 mutants in which ergosta 7,22-dienol, indicative of perturbations in sterol Δ 5,6 -desaturase (Erg3p) activity, comprised >5% of the total sterol fraction. The erg3 mutants (CA12, CA488, CA490, and CA1008) were all resistant to fluconazole, voriconazole, itraconazole, ketoconazole, and clotrimazole under standard CLSI assay conditions (MIC values, ≥256, 16, 16, 8, and 1 μg ml −1 , respectively). Importantly, CA12 and CA1008 retained an azole-resistant phenotype even when assayed in the presence of FK506, a multidrug efflux inhibitor. Conversely, CA488, CA490, and three comparator isolates (CA6, CA14, and CA177, in which ergosterol comprised >80% of the total sterol fraction and ergosta 7,22-dienol was undetectable) all displayed azole-sensitive phenotypes under efflux-inhibited assay conditions. Owing to their ergosterol content, CA6, CA14, and CA177 were highly sensitive to amphotericin B (MIC values, <0.25 μg ml −1 ); CA1008, in which ergosterol comprised <2% of the total sterol fraction, was less sensitive (MIC, 1 μg ml −1 ). CA1008 harbored multiple amino acid substitutions in Erg3p but only a single conserved polymorphism (E266D) in sterol 14α-demethylase (Erg11p). CA12 harbored one substitution (W332R) in Erg3p and no residue changes in Erg11p. CA488 and CA490 were found to harbor multiple residue changes in both Erg3p and Erg11p. The results suggest that missense mutations in ERG3 might arise in C. albicans more frequently than currently supposed and that the clinical significance of erg3 mutants, including those in which additional mechanisms also contribute to resistance, should not be discounted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Erg11, a cytochrome P450 enzyme, catalyzes the 14-methylation of lanosterol in C. albicans through three cycles13,14, each requiring two electrons from nicotinamide adenine dinucleotide phosphate (NADPH)-dependent Ncp1 reductase15,16.”
From Impairing the interaction between Erg11 and cytochrome P450 reductase Ncp1 enhances azoles’ antifungal activities (2025) · cites this paper as [13]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lower abundance of the enzyme has been observed in polyene-resistant species, which has been attributed to mutations in ERG2 [61,112], ERG3 [51], ERG5 [60], ERG6 [113], and ERG11 [60] genes, which encode enzymes involved in ergosterol synthesis.”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“several mutant ERG3 clinical isolates have been identified and reportedly possess resistance to the azole antifungals and cross-resistance to the polyene amphotericin B.”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [142]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired resistance is also rare, and involves reduced ergosterol biosynthesis and the production of alternative sterols to which amphotericin B has low affinity.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the latest cross-resistance between amphotericin B and azoles or caspofungin in Candida species are increasingly worrying [103,194,195,196,197].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [195]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 3×
“Following extensive use, resistance to antifungal azoles first emerged in HIV-positive patients (29, 31); resistant isolates are now isolated from other clinical settings, including chemotherapy and organ transplantation.”
Saville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655 · cited 1×
“Ergosterol maintains the integrity and fluidity of cell membranes (1) and consequently is understood to affect the morphology (20), virulence (30), and resistance characteristics of fungal pathogens.”
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Sanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Resistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398 · cited 6×
“b 14 -methylergosta-8,24(28)-dien-3 ,6 -diol.”
InfluentialMarichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351
Self-citationFranz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Self-citation
Research works printed but not linked: 2
- 10. Kelly, S., D. C. Lamb, and D. E. Kelly. 1999. Antifungal efflux; a major mechanism of resistance in fungi. J. Antimicrob. Chemother. 44: 36-37.
- 32. Wang, W., D. Wang, R. Y. Li, et al. 1999. A study of the resistant mechanisms of Candida albicans to azole antifungal agents. Chin. J. Derm. Venereol. 13: 3-5.
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
“albicans and Candida dubliniensis [45, 62, 64, 65].”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Antifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
Antimicrobial Agents and Chemotherapy
(2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac · Cited by 485
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418
Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors
Zhang, J., Li, L., Lv, Q., Yan, L., Wang, Y., & Jiang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00691 · Cited by 245
Kelly, S. L., & Kelly, D. E. (2013) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0476 · Cited by 230
Self-citationEvolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
Resistance to antifungals that target CYP51
Parker, J. E., Warrilow, A. G. S., Price, C. L., Mullins, J. G. L., Kelly, D. E., & Kelly, S. L. (2014) · Journal of Chemical Biology · doi:10.1007/s12154-014-0121-1 · Cited by 204
“In some species, including Candida albicans, 14α-methyl-ergosta-8,24(28)-dien-3β-6α-diol is accumulated, which is known to disrupt the cell membrane [30, 31] whilst other species, such as C.”
BackgroundSelf-citationMutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202
“albicans mechanisms of fluconazole resistance, such as loss-of-function (LOF) mutations in CaERG3, have also been reported but are much less commonly identified among clinical isolates (31).”
Self-citationFan, J., Urban, M., Parker, J. E., Brewer, H. C., Kelly, S. L., Hammond‐Kosack, K. E., Fraaije, B. A., Liu, X., & Cools, H. J. (2013) · New Phytologist · doi:10.1111/nph.12193 · Cited by 177
“…in S. cerevisiae strain YUG37::erg11, which has been used previously to assess the impact of CYP51 mutations on Mycosphaerella graminicola azole sensitivity and enzyme function (Cools et al., 2010, 2011) and to analyse the role of AfCYP51A and AfCYP51B genes in A. fumigatus (Martel et al., 2010b).”
Self-citationA New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
Kidd, S. E., Chen, S. C.-A., Meyer, W., & Halliday, C. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02903 · Cited by 166
Cools, H. J., Bayón, C., Atkins, S. L., Lucas, J. A., & FRAAIJE, B. A. (2012) · Pest Management Science · doi:10.1002/ps.3263 · Cited by 161
Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 168
Lv, Q.-Z., Yan, L., & Jiang, Y.-Y. (2016) · Virulence · doi:10.1080/21505594.2016.1188236 · Cited by 133
Beardsley, J., Halliday, C. L., Chen, S. C.-A., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 124
Forastiero, A., Mesa-Arango, A. C., Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Bernal-Martinez, L., Pelaez, T., Lopez, J. F., Grimalt, J. O., Gomez-Lopez, A., Cuesta, I., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00477-13 · Cited by 131
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
Molecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals
Eddouzi, J., Parker, J. E., Vale-Silva, L. A., Coste, A., Ischer, F., Kelly, S., Manai, M., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-13 · Cited by 128
Self-citationCurrent status of antifungal resistance and its impact on clinical practice
Alcazar‐Fuoli, L., & Mellado, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12896 · Cited by 117
Pryszcz, L. P., Németh, T., Gácser, A., & Gabaldón, T. (2014) · Genome Biology and Evolution · doi:10.1093/gbe/evu082 · Cited by 119
Morio, F., Pagniez, F., Lacroix, C., Miegeville, M., & Le Pape, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks186 · Cited by 120
Morschhäuser, J. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5628-4 · Cited by 118
Castanheira, M., Deshpande, L. M., Davis, A. P., Rhomberg, P. R., & Pfaller, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00906-17 · Cited by 114
“Target alterations in the ergosterol synthesis pathway, mainly in Erg11 (10) but also in Erg3 (11), have been associated with azole resistance development in Candida species.”
InfluentialDhingra, S., & Cramer, R. A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00092 · Cited by 115
Molecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114
Hull, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06253-11 · Cited by 113
Self-citationTreatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
Ksiezopolska, E., Schikora-Tamarit, M. À., Beyer, R., Nunez-Rodriguez, J. C., Schüller, C., & Gabaldón, T. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.084 · Cited by 107
Nishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Vale-Silva, L. A., Coste, A. T., Ischer, F., Parker, J. E., Kelly, S. L., Pinto, E., & Sanglard, D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05720-11 · Cited by 97
Self-citationHull, C. M., Bader, O., Parker, J. E., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01145-12 · Cited by 90
Self-citationBing, J., Hu, T., Zheng, Q., Muñoz, J. F., Cuomo, C. A., & Huang, G. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01466-20 · Cited by 86
The effect of biomaterials and antifungals on biofilm formation by Candida species: a review
Cuéllar‐Cruz, M., Vega‐González, A., Mendoza‐Novelo, B., López-Romero, E., Ruiz‐Baca, E., Escorza, M. A. Q., & Villagómez-Castro, J. C. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1634-6 · Cited by 104
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
In Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa
Maphanga, T. G., Naicker, S. D., Kwenda, S., Muñoz, J. F., van Schalkwyk, E., Wadula, J., Nana, T., Ismail, A., Coetzee, J., Govind, C., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00517-21 · Cited by 78
Johnston, E. J., Moses, T., & Rosser, S. J. (2020) · Yeast · doi:10.1002/yea.3452 · Cited by 74
The effect of antifungal resistance development on the virulence of Candida species
Bohner, F., Papp, C., & Gácser, A. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac019 · Cited by 83
“Nevertheless, the established existence of azole-resistant ERG3 mutants with the ability to form hyphae to bypass decreased virulence leaves an alarming opportunity for the emergence of triazole-resistant C. albicans outbreaks (Martel et al. 2010, Vale-Silva et al. 2012) (Fig.”
UPC2 Is Universally Essential for Azole Antifungal Resistance in Candida albicans
Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S., & Rogers, P. D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00221-13 · Cited by 71
Iyer, K. R., Camara, K., Daniel-Ivad, M., Trilles, R., Pimentel-Elardo, S. M., Fossen, J. L., Marchillo, K., Liu, Z., Singh, S., Muñoz, J. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20183-3 · Cited by 72
Branco, J., Ola, M., Silva, R. M., Fonseca, E. S. S., Gomes, N. C., Martins-Cruz, C., Silva, A. P., Silva-Dias, A., Pina‐Vaz, C., Erraught, C., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.002 · Cited by 75
Suchodolski, J., Muraszko, J., Bernat, P., & Krasowska, A. (2019) · Microorganisms · doi:10.3390/microorganisms7100378 · Cited by 68
Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae
Kannan, A., Asner, S. A., Trachsel, E., Kelly, S., Parker, J., & Sanglard, D. (2019) · mBio · doi:10.1128/mbio.02512-19 · Cited by 63
Self-citationErgosterol Biosynthesis and Regulation Impact the Antifungal Resistance and Virulence of Candida spp
Eliaš, D., Tóth Hervay, N., & Gbelská, Y. (2024) · Stresses · doi:10.3390/stresses4040041 · Cited by 63
“Candida kefyr CkERG2 gene is a major target conferring resistance to amphotericin B. Mutations in the CaERG3 gene and inactivation of desaturase activity have been observed in some C. albicans azole-resistant clinical isolates [27,123].”
Wang, S., Wang, Y., Liu, W., Liu, N., Zhang, Y., Dong, G., Liu, Y., Li, Z., He, X., Miao, Z., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400492t · Cited by 63
Antifungal drug resistance in Candida: a special emphasis on amphotericin B
Ahmady, L., Gothwal, M., Mukkoli, M. M., & Bari, V. K. (2024) · Apmis · doi:10.1111/apm.13389 · Cited by 65
Investigating Antifungal Susceptibility in Candida Species With MALDI-TOF MS-Based Assays
Delavy, M., Santos, A. R. D., Heiman, C. M., & Coste, A. T. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00019 · Cited by 66
Delavy, M., Cerutti, L., Croxatto, A., Prod’hom, G., Sanglard, D., Greub, G., & Coste, A. T. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03000 · Cited by 62
Salazar, S. B., Simões, R., Pedro, N. A., Pinheiro, M. J. F., Carvalho, M. F. N. N., & Mira, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6010023 · Cited by 63
Mutations associated with fungicide resistance in Colletotrichum species: A Review
Cortaga, C. Q., Cordez, B. W. P., Dacones, L. S., Balendres, M. A., & Cueva, F. M. D. (2023) · Phytoparasitica · doi:10.1007/s12600-023-01063-0 · Cited by 59
Warrilow, A. G. S., Hull, C. M., Rolley, N. J., Parker, J. E., Nes, W. D., Smith, S. N., Kelly, D. E., & Kelly, S. L. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01195-14 · Cited by 61
Self-citationRybak, J. M., Dickens, C. M., Parker, J. E., Caudle, K. E., Manigaba, K., Whaley, S. G., Nishimoto, A. T., Luna-Tapia, A., Roy, S., Zhang, Q., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00651-17 · Cited by 53
Self-citationPeraman, R., Sure, S. K., Dusthackeer, A., Chilamakuru, N. B., Reddy, Y. P., Chiranjeevi, P., Kutagulla, V. K., & Chinni, S. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00196-5 · Cited by 59
Nishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
Self-citationYun, Y., Yin, D., Dawood, D. H., Liu, X., Chen, Y., & Ma, Z. (2014) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2014.04.010 · Cited by 55
Molecular Mechanism of Drug Resistance
Ray, S., Das, S., & Suar, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_3 · Cited by 66
Toxic eburicol accumulation drives the antifungal activity of azoles against Aspergillus fumigatus
Elsaman, H., Golubtsov, E., Brazil, S., Ng, N., Klugherz, I., Martin, R., Dichtl, K., Müller, C., & Wagener, J. (2024) · Nature Communications · doi:10.1038/s41467-024-50609-1 · Cited by 54
Emerging Mechanisms of Drug Resistance in Candida albicans
Prasad, R., Nair, R., & Banerjee, A. (2019) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-13035-0_6 · Cited by 45
Mane, A., Vidhate, P., Kusro, C., Waman, V., Saxena, V., Kulkarni‐Kale, U., & Risbud, A. (2016) · Mycoses · doi:10.1111/myc.12439 · Cited by 41
Costa, C., Ribeiro, J., Miranda, I. M., Silva-Dias, A., Cavalheiro, M., Costa-de-Oliveira, S., Rodrigues, A. G., & Teixeira, M. C. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00526 · Cited by 43
A synthetic peptide mimic kills Candida albicans and synergistically prevents infection
Schaefer, S., Vij, R., Sprague, J. L., Austermeier, S., Dinh, H., Judzewitsch, P. R., Müller‐Loennies, S., Silva, T. L., Seemann, E. A., Qualmann, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50491-x · Cited by 45
Wang, J., Shi, D., Wei, L., Chen, W., Ma, W., Chen, C., & Wang, K. (2020) · Pest Management Science · doi:10.1002/ps.5964 · Cited by 42
Feng, Y., Lu, H., Whiteway, M., & Jiang, Y. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.10.019 · Cited by 40
Sun, X., Wang, W., Wang, K., Yu, X., Liu, J., Zhou, F., Xie, B., & Li, S. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00127 · Cited by 37
Wang, B., Huang, L.-H., Zhao, J.-X., Wei, M., Fang, H., Wang, D.-Y., Wang, H.-F., Yin, J.-G., & Xiang, M. (2015) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2015.08.002 · Cited by 37
Mount, H. O., Revie, N. M., Todd, R. T., Anstett, K., Collins, C., Costanzo, M., Boone, C., Robbins, N., Selmecki, A., & Cowen, L. E. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007319 · Cited by 34
Serratore, N. D., Baker, K. M., Macadlo, L. A., Gress, A. R., Powers, B. L., Atallah, N., Westerhouse, K. M., Hall, M. C., Weake, V. M., & Briggs, S. D. (2018) · Genetics · doi:10.1534/genetics.117.300554 · Cited by 33
Hull, C. M., Loveridge, E. J., Rolley, N. J., Donnison, I. S., Kelly, S. L., & Kelly, D. E. (2014) · Biotechnology for Biofuels · doi:10.1186/s13068-014-0133-7 · Cited by 33
Self-citationResistance to antifungal therapies
Prasad, R., Banerjee, A., & Shah, A. H. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160067 · Cited by 37
Binjubair, F. A., Parker, J. E., Warrilow, A. G. S., Puri, K., Braidley, P. J., Tatar, E., Kelly, S. L., Kelly, D. E., & Simons, C. (2020) · ChemMedChem · doi:10.1002/cmdc.202000250 · Cited by 31
Self-citationLu, H., Li, W., Whiteway, M., Wang, H., Zhu, S., Ji, Z., Feng, Y., Yan, L., Fang, T., Li, L., et al. (2023) · mBio · doi:10.1128/mbio.02639-22 · Cited by 30
García‐Effrón, G. (2021) · Journal of Fungi · doi:10.3390/jof7030197 · Cited by 31
Luna-Tapia, A., Willems, H. M. E., Parker, J. E., Tournu, H., Barker, K. S., Nishimoto, A. T., Rogers, P. D., Kelly, S. L., Peters, B. M., & Palmer, G. E. (2018) · mBio · doi:10.1128/mbio.00225-18 · Cited by 29
“Such mutations permit the production of at least some ergosterol but are also sufficient to induce full azole resistance in vitro (16).”
BackgroundSelf-citationRodríguez, C., Ibáñez, R., Rollins‐Smith, L. A., Gutiérrez, M., & Durant-Archibold, A. A. (2020) · Antibiotics · doi:10.3390/antibiotics9120843 · Cited by 30
Hosogaya, N., Miyazaki, T., Nagi, M., Tanabe, K., Minematsu, A., Nagayoshi, Y., Yamauchi, S., Nakamura, S., Imamura, Y., Izumikawa, K., et al. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12043 · Cited by 28
Warrilow, A. G. S., Mullins, J. G. L., Hull, C. M., Parker, J. E., Lamb, D. C., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05389-11 · Cited by 31
Self-citationGenome sequence of the opportunistic human pathogen Magnusiomyces capitatus
Brejová, B., Lichancová, H., Brázdovič, F., Hegedűsová, E., Jakúbková, M., Hodorová, V., Džugasová, V., Baláž, A., Zeiselová, L., Cillingová, A., et al. (2018) · Current Genetics · doi:10.1007/s00294-018-0904-y · Cited by 29
Emerging Complexity and the Need for Advanced Drug Delivery in Targeting Candida Species
Wadhwa, R., Pandey, P., Gupta, G., Aggarwal, T., Kumar, N., Mehta, M., Satija, S., Gulati, M., Madan, J., Dureja, H., et al. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191026105308 · Cited by 30
Scott, N. E., Erayil, S. E., Kline, S. E., & Selmecki, A. M. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-23 · Cited by 30
Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast
Ottilie, S., Goldgof, G. M., Calvet, C. M., Jennings, G. K., LaMonte, G., Schenken, J., Vigil, E., Kumar, P., McCall, L., Lopes, E. S. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b01037 · Cited by 27
Antifungal Drugs: Mechanism of Action and Resistance
Ahmed, M. Z., Rao, T., Saeed, A., Mutahir, Z., Hameed, S., Inayat, S., Shahzad, H., Ullah, N., Abaid-Ullah, M., Ibrahim, M., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-76320-6_5 · Cited by 31
Tevyashova, A. N., Efimova, S. S., Alexandrov, A. I., Omelchuk, O. A., Ghazy, E. S. M. O., Бычкова, Е. Н., Zatonsky, G. V., Grammatikova, N. E., Dezhenkova, L. G., Solovieva, S. E., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12010151 · Cited by 32
Zambuzzi-Carvalho, P. F., Tomazett, P. K., Santos, S. C., Ferri, P. H., Borges, C. L., Martins, W. S., Soares, C. M. D. A., & Pereira, M. (2013) · BMC Microbiology · doi:10.1186/1471-2180-13-227 · Cited by 29
Hu, L., Du, X., Li, T., Song, Y. J., Zai, S., Hu, X., Zhang, X., & Li, M. (2014) · Journal of Medical Microbiology · doi:10.1099/jmm.0.080200-0 · Cited by 26
Debnath, S., & Addya, S. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-660 · Cited by 24
Nishimoto, A. T., Zhang, Q., Hazlett, B., Morschhäuser, J., & Rogers, P. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00078-19 · Cited by 24
Demin, K. A., Refeld, A. G., Bogdanova, A. A., Prazdnova, E. V., Popov, I. V., Kutsevalova, O. Y., Ermakov, A. M., Bren, A. B., Rudoy, D. V., Chistyakov, V. A., et al. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09776-6 · Cited by 25
Arendrup, M. C., Lockhart, S. R., & Wiederhold, N. P. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.10.010 · Cited by 22
Nass, N. M., Farooque, S., Hind, C. K., Wand, M. E., Randall, C. P., Sutton, J. M., Seipke, R. F., Rayner, C. M., & O’Neill, A. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-17232-1 · Cited by 24
LAM Genes Contribute to Environmental Stress Tolerance but Sensibilize Yeast Cells to Azoles
Соколов, С. С., Vorobeva, M. A., Smirnova, A. I., Smirnova, E. A., Trushina, N. I., Galkina, K. V., Severin, F. F., & Кнорре, Д. А. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00038 · Cited by 25
Suchodolski, J., Muraszko, J., Bernat, P., & Krasowska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105219 · Cited by 25
Álvarez‐Pérez, S., García, M. E., Cutuli, M. T., Fermín, M. L., Daza, M. Á., Peláez, T., & Blanco, J. L. (2016) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2016.02.001 · Cited by 25
Regulation of ERG3, ERG6, and ERG11 Genes in Antifungal-Resistant isolates of Candida parapsilosis
Lotfali, E., Department of Medical Parasitology and Mycology, S. O. M., Ghajari, A., Department of Medical Parasitology and Mycology, S. O. M., Kordbacheh, P., Department of Medical Parasitology and Mycology, S. O. P. H., Zaini, F., Department of Medical Parasitology and Mycology, S. O. P. H., Mirhendi, H., Department of Medical Parasitology and Mycology, S. O. M., et al. (2017) · Iranian Biomedical Journal · doi:10.18869/acadpub.ibj.21.4.275 · Cited by 21
Gregor, J. B., Gutierrez-Schultz, V. A., Hoda, S., Baker, K. M., Saha, D., Burghaze, M. G., Vazquez, C., Burgei, K. E., & Briggs, S. D. (2023) · mSphere · doi:10.1128/msphere.00311-23 · Cited by 25
Metadata
- Authors
- Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L.
- Affiliations
- Swansea University (GB)
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Kelly, Steven L.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-11
- Volume
- 54
- Issue
- 11
- Pages
- 4527-4533
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2976150
- OpenAlex
- W2109056652
- Cited by
- 168
- References
- 39
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 11 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 12 · 2019: 13 · 2018: 11 · 2017: 21 · 2016: 8 · 2015: 4 · 2014: 13 · 2013: 10 · 2012: 9
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Funders
- Engineering and Physical Sciences Research Council
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, sterol 14α-demethylase, ergosterol, fluconazole resistance, voriconazole resistance, ketoconazole resistance, clotrimazole resistance, amphotericin B susceptibility, FK506, efflux pump inhibition, missense mutations, antifungal resistance
- MeSH terms
- Amphotericin B, Antifungal Agents, Azoles, Candida albicans, Clotrimazole, Ergosterol, Ketoconazole, Microbial Sensitivity Tests, Mutation, Oxidoreductases, Pyrimidines, Triazoles, Fluconazole, Itraconazole, Drug Resistance, Fungal, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.